EN – Stem cells, the answer to radiation sickness?

March 31, 2011 Group News

Cryo-Save offers to store stem cells for Japan

Cryo-Save Group NV (Euronext: CRYO, “Cryo-Save,” “the Group”), the leading international family stem cell bank, is offering to store autologous adult stem cells for Japan. Japan is looking to store stem cells of rescue workers that are likely to be exposed to high levels of radiation at the Fukushima nuclear power plant. Recent scientific studies have shown that stem cells are able to repair the damage caused by high radiation exposure. Japan, however, fears that it may run out of storage capacity and is asking for help. At the same time, this raises the question whether such a preventive and potentially life-saving measure should not be made available to all workers at nuclear power plants.

read more

NL – Stamcellen, een antwoord op stralingsziekte?

March 31, 2011 Group News

Cryo-Save biedt Japan opslag van stamcellen aan

Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, ‘de Groep’), de toonaangevende internationale familie-stamcelbank, biedt Japan de opslag van autologe, volwassen stamcellen aan. Japan wil preventief stamcellen opslaan van de reddingswerkers die in de kerncentrale van Fukushima aan hoge straling zullen worden blootgesteld. Recente wetenschappelijke studies tonen aan dat stamcellen de schade door hoge radioactieve straling kunnen herstellen. Japan vreest een tekort aan opslagcapaciteit en vraagt hulp. Tegelijkertijd opent dit de discussie of een dergelijke preventieve en potentieel levensreddende maatregel niet ter beschikking moet komen van alle werknemers in kerncentrales?

read more

EN – Director/PDMR shareholding

August 2, 2010 Group News

Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), Europe’s leading stem cell bank, has been informed today that Mr Marc Waeterschoot, Executive Director, purchased 23,850 ordinary shares of Euro 0.10 (‘Ordinary Shares’) at a price range between €5.64 and €5.80 between 26 July and 30 July 2010.

Following this purchase, Marc Waeterschoot is beneficially interested in 1,833,850 ordinary shares, representing approximately 19.84% of the Group’s issued share capital.

read more

NL – Director/PDMR shareholding

August 2, 2010 Group News

Aankoop aandelen Executive Director

Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, of ‘de Groep’), de grootste stamcelbank van Europa, is vandaag geïnformeerd dat de heer Marc Waeterschoot, Executive Director, 23.850 aandelen Cryo-Save heeft gekocht in de periode van 26 juli tot en met 30 juli. De aankoopprijs lag tussen €5,64 en €5,80.

Het aandelenbelang in de Groep van de heer Waeterschoot na deze transacties bedraagt 1.833.850 aandelen, ofwel 19.84% van het geplaatst aandelenkapitaal van de Groep.

read more

EN – Director/PDMR Shareholding

April 12, 2010 Group News

Cryo-Save Group N.V.(AIM/Euronext: CRYO, or ‘the Group’), Europe’s leading stem cell bank, has been informed that Mr Marc Waeterschoot, Chief Executive Officer, purchased 17,296 ordinary shares of Euro 0.10 (‘Ordinary Shares’) at a price range between €5.66 and €5.70 between 7 April and 9 April 2010.

Following these purchases, Marc Waeterschoot is beneficially interested in 1,810,000 ordinary shares, representing approximately 19.60% of the Group’s issued share capital.

read more

NL – Director/PDMR Shareholding

April 12, 2010 Group News

Cryo-Save Group N.V. (AIM/Euronext: CRYO, of “de Groep”), de grootste stamcelbank van Europa is geïnformeerd dat de heer Marc Waeterschoot, Chief Executive Officer, 17.296 aandelen Cryo-Save heeft gekocht in de periode van 7 april tot en met 9 april 2010. De aankoopprijs lag tussen €5,66 en €5,70.

Het aandelenbelang in de Groep van de heer Waeterschoot na deze transacties bedraagt 1.810.000 aandelen, ofwel 19,60% van het geplaatst aandelenkapitaal van de Groep.

read more

Director/PDMR Shareholding

March 26, 2010 Group News

Cryo-Save Group N.V., Europe’s leading stem cell bank, has been informed that on 25 March 2010 Marc Waeterschoot, Chief Executive Officer, transferred 100,000 ordinary shares of Euro 0.10 (‘Ordinary Shares’) from Life-Sciences N.V., a company controlled by him, into his personal Cryo-Save holdings.

As a result of the transaction, Marc Waeterschoot’s beneficial interest in Cryo-Save remains unchanged at 1,792,704 Ordinary Shares, representing approximately 19.41% of the Company’s issued share capital.

read more

NL – Non-executive director appointment

March 19, 2010 Group News

Cryo-Save benoemt Ronald Lorijn tot Non-Executive director

Cryo-Save Group N.V. (AIM/Euronext: CRYO), Europa’s grootste stamcelbank, maakt bekend dat dr. Ronald H.W. Lorijn (58) (MD, PhD, MBA) tijdens de komende Algemene Vergadering van Aandeelhouders van de onderneming op 19 mei aanstaande zal worden voorgedragen voor benoeming tot Non-Executive Director en lid van de Board van Cryo-Save Group.

read more

Page 1 of 3123